Tetherex licenses adenovirus vaccine platform from Mayo Clinic

By The Science Advisory Board staff writers

July 6, 2021 -- Tetherex Pharmaceuticals has obtained an exclusive worldwide license for the development and commercialization of a novel single-cycle adenovirus vaccine platform from the Mayo Clinic. The platform will be used to target multiple infectious diseases beginning with a COVID-19 vaccine.

The single-cycle adenovirus platform was developed to enhance the expression of target antigens to amplify immune responses to infectious disease targets. Tetherex is investigating the technology in a phase I open-label study designed to assess the safety, reactogenicity, and immunogenicity of a single-cycle adenovirus vaccine candidate against COVID-19.

The trial is expected to enroll up to 80 healthy volunteers and includes both a single ascending dose group and multiple dose group via either intramuscular or intranasal administration.

Financial details regarding the license agreement were not disclosed.

Sorrento subsidiary to develop ADC cancer therapies
Sorrento Therapeutics has formed a subsidiary company called Adnab that will develop and commercialize a Mayo Clinic-developed technology platform for...
A bright new tactic in the fight against cardiovascular disease
A new system using reporter proteins has been developed by researchers at Carnegie, Johns Hopkins University, and the Mayo Clinic that uses high-throughput...

Copyright © 2021 scienceboard.net

CPhI North America
August 10-12
Philadelphia, Pennsylvania United States
Bioprocessing Summit
August 16-19
Boston, Massachusetts United States
6th Annual CAR-TCR Summit
August 30 - September 2
European Congress of Immunology (ECI) 2021
September 1-4
Belgrade Serbia
Medical Affairs Strategic Summit (MASS)
September 13-15
New Brunswick, New Jersey United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter